FIELD: medicine.
SUBSTANCE: invention relates to medicine. That is ensured by administering a therapeutically effective amount of at least one recombinant alkaline phosphatase having the sequence SEQ ID NO: 1, wherein the subject is insensitive to the treatment of convulsions with vitamin B6.
EFFECT: invention refers to treating convulsions in a human subject having abnormal levels of at least one substrate of alkaline phosphatase selected from pyridoxal-5'-phosphate (PLP), inorganic pyrophosphate (PPi) and phosphoethanolamine (PEA).
29 cl, 14 dwg, 5 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF MUSCULAR WEAKNESS WITH ALKALINE PHOSPHATASES | 2017 |
|
RU2754558C2 |
| HYBRID PROTEINS ALIKE ALKALINE PHOSPHATASE | 2015 |
|
RU2683635C2 |
| PRODUCTION OF ALKALINE PHOSPHATASES | 2016 |
|
RU2801121C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING ERYTHROCYTES CONTAINING ENZYME DEPENDENT ON PYRIDOXALPHOSPHATE AND COFACTOR THEREOF | 2015 |
|
RU2744659C2 |
| DEGARELIX THERAPY OF METASTATIC STAGE OF PROSTATE CANCER | 2009 |
|
RU2504394C2 |
| Oxy133 OXYSTEROL ANALOGUE INDUCTS OSTEOGENESIS AND SIGNAL WAY HEDGEHOG AND INHIBITED LIPOGENESIS | 2013 |
|
RU2632191C2 |
| METHODS OF TREATING DRAVET SYNDROME | 2018 |
|
RU2767661C2 |
| PRODUCTION OF ALKALINE PHOSPHATASES | 2016 |
|
RU2745528C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ERYTHROCYTES IN WHICH AN ENZYME DEPENDENT ON PYRIDOXALPHOSPHATE IS ENCLOSED, AND COFACTOR THEREOF | 2015 |
|
RU2697086C2 |
| METHODS AND MATERIALS FOR TREATMENT OF POMPE DISEASE | 2013 |
|
RU2644258C2 |
